Key result
Subjects with GH-1 gene splice site mutations (5'IVS +1/+2 bp) were more likely to develop additional pituitary hormone deficiencies during follow-up.
Why the study?
Do patients with autosomal dominant isolated growth hormone deficiency develop other pituitary hormone deficiencies over time?
Cohort (n=57)
Yes
Do patients with autosomal dominant isolated growth hormone deficiency develop other pituitary hormone deficiencies over time?
Patients with autosomal dominant isolated growth hormone deficiency should be monitored closely over time as they may develop multiple pituitary hormone deficiencies.
May support closer monitoring in GH-1 splice-site carriers; leaves open whether surveillance improves outcomes in autosomal dominant IGHD.
Four distinct familial types of isolated GH deficiency have been described so far, of which type II is the autosomal dominant inherited form. It is mainly caused by mutations within the first 6 bp of intervening sequence 3. However, other splice site and missense mutations have been reported. Based on in vitro experiments and transgenic animal data, there is strong evidence that there is a wide variability in phenotype in terms of the severity of GH deficiency. Therefore, we studied a total of 57 subjects belonging to 19 families suffering from different splice site as well as missense mutations within the GH-1 gene. The subjects presenting with a splice site mutation within the first 2 bp of intervening sequence 3 (5'IVS +1/+2 bp) leading to a skipping of exon 3 were found to be more likely to present in the follow-up with other pituitary hormone deficiencies. In addition, although the patients with missense mutations have previously been reported to be less affected, a number of patients presenting with the P89L missense GH form, showed some pituitary hormone impairment. The development of multiple hormonal deficiencies is not age dependent, and there is a clear variability in onset, severity, and progression, even within the same families. The message of clinical importance from these studies is that the pituitary endocrine status of all such patients should continue to be monitored closely over the years because further hormonal deficiencies may evolve with time.
No takes yet. Share an insight, caveat, or question.
Mullis et al. (2005) conducted a cohort in Isolated Autosomal Dominant Growth Hormone Deficiency (n=57). GH-1 gene mutations (splice site and missense) was evaluated on Development of other pituitary hormone deficiencies. Subjects with GH-1 gene splice site mutations (5'IVS +1/+2 bp) were more likely to develop additional pituitary hormone deficiencies during follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: